A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
825 patients around the world
Available in Spain, United States, Argentina
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency
in adults with refractory chronic cough (including unexplained chronic cough) at 12 weeks.
Bellus Health Inc
13Research sites
825Patients around the world
Requirements for the patient
To 80 Years
All Gender
Medical requirements
Sites
Instituto del Buen Aire
Junín 2370, Santa Fe
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires